149 related articles for article (PubMed ID: 17172409)
1. Inhibition of phosphatidylinositol-3-kinase and mitogen-activated protein kinase kinase 1/2 prevents melanoma development and promotes melanoma regression in the transgenic TPRas mouse model.
Bedogni B; Welford SM; Kwan AC; Ranger-Moore J; Saboda K; Powell MB
Mol Cancer Ther; 2006 Dec; 5(12):3071-7. PubMed ID: 17172409
[TBL] [Abstract][Full Text] [Related]
2. Topical treatment with inhibitors of the phosphatidylinositol 3'-kinase/Akt and Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathways reduces melanoma development in severe combined immunodeficient mice.
Bedogni B; O'Neill MS; Welford SM; Bouley DM; Giaccia AJ; Denko NC; Powell MB
Cancer Res; 2004 Apr; 64(7):2552-60. PubMed ID: 15059911
[TBL] [Abstract][Full Text] [Related]
3. MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720.
Jiang CC; Lai F; Thorne RF; Yang F; Liu H; Hersey P; Zhang XD
Clin Cancer Res; 2011 Feb; 17(4):721-30. PubMed ID: 21088259
[TBL] [Abstract][Full Text] [Related]
4. Inactivation of the antiapoptotic phosphatidylinositol 3-kinase-Akt pathway by the combined treatment of taxol and mitogen-activated protein kinase kinase inhibition.
MacKeigan JP; Taxman DJ; Hunter D; Earp HS; Graves LM; Ting JP
Clin Cancer Res; 2002 Jul; 8(7):2091-9. PubMed ID: 12114408
[TBL] [Abstract][Full Text] [Related]
5. Signal transduction of MEK/ERK and PI3K/Akt activation by hypoxia/reoxygenation in renal epithelial cells.
Kwon DS; Kwon CH; Kim JH; Woo JS; Jung JS; Kim YK
Eur J Cell Biol; 2006 Nov; 85(11):1189-99. PubMed ID: 16860436
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase activity in MCF-7 cells prevents estrogen-induced mitogenesis.
Lobenhofer EK; Huper G; Iglehart JD; Marks JR
Cell Growth Differ; 2000 Feb; 11(2):99-110. PubMed ID: 10714766
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of phosphatidylinositol-3 kinase/Akt or mitogen-activated protein kinase signaling sensitizes endothelial cells to TNF-alpha cytotoxicity.
Zhang L; Himi T; Morita I; Murota S
Cell Death Differ; 2001 May; 8(5):528-36. PubMed ID: 11423913
[TBL] [Abstract][Full Text] [Related]
8. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
Guenther MK; Graab U; Fulda S
Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia enhances FGF2- and VEGF-stimulated human placental artery endothelial cell proliferation: roles of MEK1/2/ERK1/2 and PI3K/AKT1 pathways.
Wang K; Jiang YZ; Chen DB; Zheng J
Placenta; 2009 Dec; 30(12):1045-51. PubMed ID: 19892399
[TBL] [Abstract][Full Text] [Related]
10. Divergence in the anti-apoptotic signalling pathways used by nerve growth factor and basic fibroblast growth factor (bFGF) in PC12 cells: rescue by bFGF involves protein kinase C delta.
Wert MM; Palfrey HC
Biochem J; 2000 Nov; 352 Pt 1(Pt 1):175-82. PubMed ID: 11062070
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Mek 1/2 kinase activity and stimulation of melanogenesis by 5,7-dimethoxycoumarin treatment of melanoma cells.
Alesiani D; Cicconi R; Mattei M; Bei R; Canini A
Int J Oncol; 2009 Jun; 34(6):1727-35. PubMed ID: 19424591
[TBL] [Abstract][Full Text] [Related]
12. Crosstalk between Raf/MEK/ERK and PI3K/AKT in suppression of Bax conformational change by Grp75 under glucose deprivation conditions.
Yang L; Guo W; Zhang Q; Li H; Liu X; Yang Y; Zuo J; Liu W
J Mol Biol; 2011 Dec; 414(5):654-66. PubMed ID: 21964438
[TBL] [Abstract][Full Text] [Related]
13. Roles of the MEK1/2 and AKT pathways in CXCL12/CXCR4 induced cholangiocarcinoma cell invasion.
Leelawat K; Leelawat S; Narong S; Hongeng S
World J Gastroenterol; 2007 Mar; 13(10):1561-8. PubMed ID: 17461449
[TBL] [Abstract][Full Text] [Related]
14. Fibroblast growth factor-2 and -4 promote the proliferation of bone marrow mesenchymal stem cells by the activation of the PI3K-Akt and ERK1/2 signaling pathways.
Choi SC; Kim SJ; Choi JH; Park CY; Shim WJ; Lim DS
Stem Cells Dev; 2008 Aug; 17(4):725-36. PubMed ID: 18788932
[TBL] [Abstract][Full Text] [Related]
15. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases.
Smalley KS; Haass NK; Brafford PA; Lioni M; Flaherty KT; Herlyn M
Mol Cancer Ther; 2006 May; 5(5):1136-44. PubMed ID: 16731745
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of survival by LPA via Erk1/Erk2 and PI 3-kinase/Akt pathways in a murine hepatocyte cell line.
Sautin YY; Crawford JM; Svetlov SI
Am J Physiol Cell Physiol; 2001 Dec; 281(6):C2010-9. PubMed ID: 11698260
[TBL] [Abstract][Full Text] [Related]
17. Cooperative regulation of the cell division cycle by the protein kinases RAF and AKT.
Mirza AM; Gysin S; Malek N; Nakayama K; Roberts JM; McMahon M
Mol Cell Biol; 2004 Dec; 24(24):10868-81. PubMed ID: 15572689
[TBL] [Abstract][Full Text] [Related]
18. The MAPK pathway as an apoptosis enhancer in melanoma.
Haydn JM; Hufnagel A; Grimm J; Maurus K; Schartl M; Meierjohann S
Oncotarget; 2014 Jul; 5(13):5040-53. PubMed ID: 24970815
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of either phosphatidylinositol 3-kinase/Akt or the mitogen/extracellular-regulated kinase, MEK/ERK, signaling pathways suppress growth of breast cancer cell lines, but MEK/ERK signaling is critical for cell survival.
Ripple MO; Kalmadi S; Eastman A
Breast Cancer Res Treat; 2005 Sep; 93(2):177-88. PubMed ID: 16187238
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin inhibits hepatic growth hormone receptor and insulin-like growth factor I mRNA expression by activating the ERK and PI3K signaling pathways.
Hagemeister AL; Sheridan MA
Am J Physiol Regul Integr Comp Physiol; 2008 Aug; 295(2):R490-7. PubMed ID: 18495839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
